Moomoo AI 已提取核心訊息
Recursion Pharmaceuticals, Inc. reported on February 6, 2024, that Dr. Shafique Virani has transitioned from his role as Chief Business Officer to become a Senior Strategic Advisor. In his new capacity, Dr. Virani will continue to support the company's business development and further its mission. Concurrently, Matthew Kinn, previously Senior Vice President of Business Development and Corporate Initiatives, has been promoted to the executive team, taking over the responsibilities of Dr. Virani. Mr. Kinn has been with Recursion since 2017 and has a background with the Boston Consulting Group. As part of the transition, Dr. Virani has entered into agreements with Recursion that include advisory fees, continued equity vesting, COBRA premium payments, and a potential lump sum payment should the agreement terminate early. The company plans to file these agreements as exhibits in a periodic report.
Recursion Pharmaceuticals, Inc. reported on February 6, 2024, that Dr. Shafique Virani has transitioned from his role as Chief Business Officer to become a Senior Strategic Advisor. In his new capacity, Dr. Virani will continue to support the company's business development and further its mission. Concurrently, Matthew Kinn, previously Senior Vice President of Business Development and Corporate Initiatives, has been promoted to the executive team, taking over the responsibilities of Dr. Virani. Mr. Kinn has been with Recursion since 2017 and has a background with the Boston Consulting Group. As part of the transition, Dr. Virani has entered into agreements with Recursion that include advisory fees, continued equity vesting, COBRA premium payments, and a potential lump sum payment should the agreement terminate early. The company plans to file these agreements as exhibits in a periodic report.
Recursion Pharmicals, Inc.於2024年2月6日報告稱，沙菲克·維拉尼博士已從首席商務官的職位過渡到高級戰略顧問。在新的職位上，維拉尼博士將繼續支持公司的業務發展並推進其使命。同時，曾任業務發展和企業計劃高級副總裁的馬修·金恩已晉升爲執行團隊，接替維拉尼博士的職責。Kinn先生自2017年以來一直在Recursion工作，擁有波士頓諮詢集團的背景。作爲過渡的一部分，維拉尼博士已與Recursion簽訂了協議，其中包括諮詢費、持續股權歸屬、COBRA保費支付以及協議提前終止後可能的一次性付款。該公司計劃將這些協議作爲證物提交定期報告。
Recursion Pharmicals, Inc.於2024年2月6日報告稱，沙菲克·維拉尼博士已從首席商務官的職位過渡到高級戰略顧問。在新的職位上，維拉尼博士將繼續支持公司的業務發展並推進其使命。同時，曾任業務發展和企業計劃高級副總裁的馬修·金恩已晉升爲執行團隊，接替維拉尼博士的職責。Kinn先生自2017年以來一直在Recursion工作，擁有波士頓諮詢集團的背景。作爲過渡的一部分，維拉尼博士已與Recursion簽訂了協議，其中包括諮詢費、持續股權歸屬、COBRA保費支付以及協議提前終止後可能的一次性付款。該公司計劃將這些協議作爲證物提交定期報告。
有用
沒用
